HALIFAX, Feb. 20 /CNW/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine
development company, announced today the appointment of former senator,
Michael Kirby, as the new Board of Directors Chair. Michael Kirby succeeds the
late Dr. Warrick Kimmins, who provided exemplary leadership during his tenure
and was instrumental in spinning out IVT's novel technology from Dalhousie
"I am passionate about advancing health care and am delighted to be part
of such a fast-growing biotech company," said former senator Michael Kirby.
"IVT has an impressive track record and its patented technology holds
tremendous potential to improve vaccines worldwide. "
"Michael Kirby is an internationally respected leader in health care,"
said Dr. Randal Chase, IVT President and CEO. "His strategic advice will be
invaluable, as we enter the next phase of development with the expectation of
beginning a new Phase 1 clinical trial in 2009."
The Honourable Michael Kirby has had a distinguished career spanning
academia, business, provincial, and federal public service. Most recently, he
was appointed, by Prime Minister Stephen Harper, to be the first Chair of the
Mental Health Commission of Canada. He also serves on several boards including
The Bank of Nova Scotia, Extendicare, Ontario Energy Savings Income Trust,
MDC Partners, and Indigo Books and Music.
Senator Kirby was past chair of the Standing Senate Committee on Social
Affairs, Science and Technology. He has been a member of the Trilateral
Commission, the Council of the International Institute for Applied Systems
Analysis, Luxemburg, Austria, and the Club of Rome. He was also a full-time
professor in the School of Business Administration and the School of Public
Administration at Dalhousie University.
ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine
development company. Through its own biotech research and collaborations with
partners, IVT creates vaccines with the potential to help save and improve
lives around the world.
The company, using its proprietary VacciMax(R) platform, is able to
stimulate an earlier, more powerful, long lasting immune response that could
provide a new way to treat cancer and infectious diseases.
In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based
Immunotope Inc. The acquisition enables IVT to create an entire pipeline of
proprietary therapeutic cancer and infectious-disease specific vaccines. In
January 2008, IVT licensed its technology to Pfizer Animal health, marking a
pivotal step in achieving its vision of delivering breakthrough vaccines.
For further information:
For further information: Brian Lowe, Vice President IVT, (902) 492-1819,
firstname.lastname@example.org; Jennifer Ayotte, Communications, (902) 209-4704,